Relay Therapeutics, Inc. (RLAY)
NASDAQ: RLAY · Real-Time Price · USD
4.760
+0.130 (2.81%)
Feb 5, 2025, 11:48 AM EST - Market open
Relay Therapeutics Revenue
Relay Therapeutics had revenue of $10.01M in the twelve months ending September 30, 2024, down -61.22% year-over-year. In the year 2023, Relay Therapeutics had annual revenue of $25.55M with 1,749.82% growth.
Revenue (ttm)
$10.01M
Revenue Growth
-61.22%
P/S Ratio
61.16
Revenue / Employee
$30,978
Employees
323
Market Cap
795.91M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
Novartis AG | 51.72B |
AstraZeneca | 51.21B |
Thermo Fisher Scientific | 42.88B |
Abbott Laboratories | 41.95B |
RLAY News
- 4 weeks ago - Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival - GlobeNewsWire
- 2 months ago - Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium - GlobeNewsWire
- 2 months ago - Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors - GlobeNewsWire
- 2 months ago - Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors - GlobeNewsWire
- 3 months ago - Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights - GlobeNewsWire
- 3 months ago - Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024 - GlobeNewsWire
- 5 months ago - Relay Therapeutics: 2nd-Line RLY-2608 Data Moves Program Towards Expansion - Seeking Alpha